TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia
Improvements in patient-centered outcomes were observed across cohorts, with the largest improvements observed for patients who began TV-46000 during SHINE (ie, de novo and placebo rollover cohorts), while gains made during RISE were minimally improved or maintained in the TV-46000 rollover cohort, indicating the benefit of uninterrupted TV-46000 treatment. These data support the effectiveness of TV-46000 to improve patient-centered outcomes in patients with schizophrenia.
Authors
- John M. Kane (ORCID: https://orcid.org/0000-0002-2628-9442)
- Leslie Citrome (ORCID: https://orcid.org/0000-0002-6098-9266)
- Orna Tohami
- Roy Eshet
- Anna Elgart
- Eran Harary
- K.R. Franzenburg
- Mark Suett (ORCID: https://orcid.org/0000-0002-6840-1535)
- Glen Davis rd
- Marko A. Mychaskiw
Institutions
- Northwell Health (US)
- Feinstein Institute for Medical Research (US)
- New York Medical College (US)
- Donald & Barbara Zucker School of Medicine at Hofstra/Northwell (US)
- Teva Pharmaceuticals (Israel) (IL)
- Teva Pharmaceuticals (United States) (US)
- Zucker Hillside Hospital (US)
Publication Details
- Journal
- Neuropsychiatric Disease and Treatment
- Published
- 2024-10-01
- DOI
- https://doi.org/10.2147/ndt.s459104
- Citations
- 3
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Teva Pharmaceutical Industries